Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-22-146362
Filing Date
2022-05-10
Accepted
2022-05-10 16:34:06
Documents
85
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d327432d10q.htm   iXBRL 10-Q 1858965
2 EX-5.1 d327432dex51.htm EX-5.1 8804
3 EX-10.2 d327432dex102.htm EX-10.2 61302
4 EX-10.3 d327432dex103.htm EX-10.3 13594
5 EX-10.4 d327432dex104.htm EX-10.4 801712
6 EX-31.1 d327432dex311.htm EX-31.1 10312
7 EX-31.2 d327432dex312.htm EX-31.2 10354
8 EX-32.1 d327432dex321.htm EX-32.1 4504
9 EX-32.2 d327432dex322.htm EX-32.2 4546
10 EX-99.1 d327432dex991.htm EX-99.1 166041
16 GRAPHIC g327432g0510060627871.jpg GRAPHIC 2533
  Complete submission text file 0001193125-22-146362.txt   9410474

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20220331.xsd EX-101.SCH 53817
12 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rvnc-20220331_cal.xml EX-101.CAL 104401
13 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvnc-20220331_def.xml EX-101.DEF 258199
14 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20220331_lab.xml EX-101.LAB 653407
15 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20220331_pre.xml EX-101.PRE 430316
79 EXTRACTED XBRL INSTANCE DOCUMENT d327432d10q_htm.xml XML 1327367
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 22910289
SIC: 2834 Pharmaceutical Preparations